103 related articles for article (PubMed ID: 7799058)
1. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Mure A; Plouin PF; Caillou B; Parmentier C
J Nucl Med; 1995 Jan; 36(1):1-6. PubMed ID: 7799058
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Comparative Study of 18 F-FDOPA PET/CT Versus 123 I-MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma.
Sung C; Lee HS; Lee DY; Kim YI; Kim JE; Lee SJ; Oh SJ; Sung TY; Lee YM; Kim YH; Kim BJ; Koh JM; Lee SH; Ryu JS
Clin Nucl Med; 2024 Jan; 49(1):27-36. PubMed ID: 38054497
[TBL] [Abstract][Full Text] [Related]
3. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma.
Ilanchezhian M; Jha A; Pacak K; Del Rivero J
Curr Treat Options Oncol; 2020 Aug; 21(11):85. PubMed ID: 32862332
[TBL] [Abstract][Full Text] [Related]
4. Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma.
Jimenez C; Chin BB; Noto RB; Dillon JS; Solnes L; Stambler N; DiPippo VA; Pryma DA
Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36472300
[TBL] [Abstract][Full Text] [Related]
5. CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (
Grand-Guillaume J; Mansi R; Gaonkar RH; Zanger S; Fani M; Eugster PJ; Beck Popovic M; Grouzmann E; Abid K
J Transl Med; 2023 Sep; 21(1):604. PubMed ID: 37679770
[TBL] [Abstract][Full Text] [Related]
6. MALIGNANT PARAGANGLIOMA NON-RESPONSIVE TO MIBG IN MEN2A SYNDROME.
Lider S; Gheorghiu M; Milos I; Badiu C
Acta Endocrinol (Buchar); 2022; 18(4):536-537. PubMed ID: 37152873
[No Abstract] [Full Text] [Related]
7. Usefulness of semi-quantitative analysis in
Kitamura Y; Baba S; Isoda T; Maruoka Y; Sasaki M; Nishie A; Ishigami K
Ann Nucl Med; 2022 Jan; 36(1):95-102. PubMed ID: 34826059
[TBL] [Abstract][Full Text] [Related]
8. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.
Taïeb D; Hicks RJ; Hindié E; Guillet BA; Avram A; Ghedini P; Timmers HJ; Scott AT; Elojeimy S; Rubello D; Virgolini IJ; Fanti S; Balogova S; Pandit-Taskar N; Pacak K
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2112-2137. PubMed ID: 31254038
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma.
Tan TH; Hussein Z; Saad FF; Shuaib IL
Nucl Med Mol Imaging; 2015 Jun; 49(2):143-51. PubMed ID: 26085860
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of pheochromocytoma: a practical guide to clinicians.
Pappachan JM; Raskauskiene D; Sriraman R; Edavalath M; Hanna FW
Curr Hypertens Rep; 2014 Jul; 16(7):442. PubMed ID: 24792093
[TBL] [Abstract][Full Text] [Related]
11. Current concepts in the management of adrenal incidentalomas.
Kanagarajah P; Ayyathurai R; Manoharan M; Narayanan G; Kava BR
Urol Ann; 2012 Sep; 4(3):137-44. PubMed ID: 23248518
[TBL] [Abstract][Full Text] [Related]
12. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.
Taïeb D; Timmers HJ; Hindié E; Guillet BA; Neumann HP; Walz MK; Opocher G; de Herder WW; Boedeker CC; de Krijger RR; Chiti A; Al-Nahhas A; Pacak K; Rubello D;
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1977-95. PubMed ID: 22926712
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor SPECT.
Pepe G; Moncayo R; Bombardieri E; Chiti A
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S41-51. PubMed ID: 22388628
[TBL] [Abstract][Full Text] [Related]
14. Contrast- and non-contrast-enhanced ultrasonography (US) findings of hepatic metastasis from malignant pheochromocytoma/paraganglioma.
Nakano S; Tsushima Y; Higuchi T; Taketomi-Takahashi A; Amanuma M
Jpn J Radiol; 2012 May; 30(4):310-6. PubMed ID: 22271156
[TBL] [Abstract][Full Text] [Related]
15. Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.
Gimm O; DeMicco C; Perren A; Giammarile F; Walz MK; Brunaud L
Langenbecks Arch Surg; 2012 Feb; 397(2):155-77. PubMed ID: 22124609
[TBL] [Abstract][Full Text] [Related]
16. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
Kroiss A; Putzer D; Uprimny C; Decristoforo C; Gabriel M; Santner W; Kranewitter C; Warwitz B; Waitz D; Kendler D; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):865-73. PubMed ID: 21279352
[TBL] [Abstract][Full Text] [Related]
17. A large pheochromocytoma with invasion of multiple local organs.
Zhu D; Kumar A; Weintraub WS; Rahman E
J Clin Hypertens (Greenwich); 2011 Jan; 13(1):60-4. PubMed ID: 21214723
[No Abstract] [Full Text] [Related]
18. Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT.
Tan EH; Goh SW
World J Radiol; 2010 Feb; 2(2):55-67. PubMed ID: 21160919
[TBL] [Abstract][Full Text] [Related]
19. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
Hicks RJ
Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S83-91. PubMed ID: 20880795
[TBL] [Abstract][Full Text] [Related]
20. New imaging approaches to phaeochromocytomas and paragangliomas.
Havekes B; King K; Lai EW; Romijn JA; Corssmit EP; Pacak K
Clin Endocrinol (Oxf); 2010 Feb; 72(2):137-45. PubMed ID: 19508681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
